KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teladoc Health (TDOC) Capital Expenditures (2016 - 2025)

Teladoc Health's Capital Expenditures history spans 12 years, with the latest figure at $2.6 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 97.59% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $8.9 million, down 92.15%, while the annual FY2025 figure was $8.9 million, 92.15% down from the prior year.
  • Capital Expenditures for Q4 2025 was $2.6 million at Teladoc Health, up from -$51.6 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $108.6 million in Q4 2024 and bottomed at -$55.5 million in Q3 2024.
  • The 5-year median for Capital Expenditures is $28.9 million (2025), against an average of $23.9 million.
  • The largest YoY upside for Capital Expenditures was 4221.96% in 2021 against a maximum downside of 1391.39% in 2021.
  • A 5-year view of Capital Expenditures shows it stood at $49.8 million in 2021, then fell by 4.2% to $47.7 million in 2022, then dropped by 26.4% to $35.1 million in 2023, then surged by 209.39% to $108.6 million in 2024, then crashed by 97.59% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for TDOC's Capital Expenditures are $2.6 million (Q4 2025), -$51.6 million (Q3 2025), and $29.0 million (Q2 2025).